You are using an outdated browser. We suggest you update your browser for a better experience. Click here for update.
Close this notification.
Skip to main content Skip to search

 

420 Results
The High Cost Therapy Funding Program primarily funds high-cost injectable or oral cancer drugs given in inpatient units of the hospital. The...
Document
Document
Les fournisseurs de soins primaires sont le premier point de contact pour les femmes, les personnes trans et les personnes non binaires qui peuvent...
Drug
Other Name(s): Sarclisa®
Mar 2024
Document
Le mot « poitrine » est parfois utilisé pour désigner les seins. Certaines personnes, y compris les hommes transgenres, les personnes transmasculines...
Regimen
Cancer Type:
Hematologic, 
Leukemia - Chronic Lymphocytic (CLL)
Intent: Palliative
Funding:
Exceptional Access Program
    iBRUtinib - For the treatment of patients with chronic lymphocytic leukemia (CLL), in combination with venetoclax, based on criteria
Exceptional Access Program
    venetoclax - For the treatment of patients with chronic lymphocytic leukemia (CLL), in combination with ibrutinib, based on criteria
Aug 2025

Pages